In MM, mAbs targeting CD40, such as SGN-40 (dacetuzumab), have demonstrated cytotoxic effects against MM cell lines and shown favorable safety profile, though clinical responses in trials were only modest (NCT00079716, NCT00664898) [21]. This evidence concerns the gene CD40 and Miyoshi myopathy.